Emmessar Biotech & Nutrition Ltd
₹ 35.0
-2.18%
30 Apr
- close price
About
Incorporated in 1992, Emmessar Biotech & Nutrition Ltd is in the business of Healthcare, Fine Chemicals and Renting of Immovable property[1]
Key Points
- Market Cap ₹ 17.5 Cr.
- Current Price ₹ 35.0
- High / Low ₹ 64.0 / 27.2
- Stock P/E 54.8
- Book Value ₹ 15.4
- Dividend Yield 0.00 %
- ROCE 12.6 %
- ROE 4.23 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company's working capital requirements have reduced from 116 days to 41.9 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 7.47% over last 3 years.
- Earnings include an other income of Rs.2.01 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1.37 | 2.19 | 1.98 | 2.61 | 1.27 | 0.63 | 3.40 | 6.99 | 0.36 | 1.02 | 0.56 | 0.61 | |
1.43 | 2.34 | 2.66 | 2.38 | 1.67 | 1.27 | 3.81 | 6.15 | 1.26 | 1.71 | 1.64 | 1.56 | |
Operating Profit | -0.06 | -0.15 | -0.68 | 0.23 | -0.40 | -0.64 | -0.41 | 0.84 | -0.90 | -0.69 | -1.08 | -0.95 |
OPM % | -4.38% | -6.85% | -34.34% | 8.81% | -31.50% | -101.59% | -12.06% | 12.02% | -250.00% | -67.65% | -192.86% | -155.74% |
0.09 | 0.06 | 0.03 | 0.98 | 1.25 | 1.01 | 1.21 | 1.47 | 1.92 | 1.75 | 1.99 | 2.01 | |
Interest | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.20 | 0.07 | 0.03 | 0.01 | 0.05 | 0.08 | 0.06 | 0.06 | 0.09 | 0.09 | 0.10 | 0.10 |
Profit before tax | -0.17 | -0.16 | -0.68 | 1.19 | 0.80 | 0.29 | 0.74 | 2.25 | 0.93 | 0.97 | 0.81 | 0.96 |
Tax % | 82.35% | -25.00% | -30.88% | 0.00% | -15.00% | -82.76% | -2.70% | 36.00% | 48.39% | 47.42% | 7.41% | 66.67% |
-0.31 | -0.12 | -0.47 | 1.19 | 0.91 | 0.53 | 0.75 | 1.45 | 0.48 | 0.50 | 0.75 | 0.32 | |
EPS in Rs | -0.62 | -0.24 | -0.94 | 2.38 | 1.82 | 1.06 | 1.50 | 2.90 | 0.96 | 1.00 | 1.50 | 0.64 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -12% |
5 Years: | -29% |
3 Years: | 19% |
TTM: | 9% |
Compounded Profit Growth | |
---|---|
10 Years: | 17% |
5 Years: | -20% |
3 Years: | -13% |
TTM: | -57% |
Stock Price CAGR | |
---|---|
10 Years: | 9% |
5 Years: | 23% |
3 Years: | 0% |
1 Year: | -15% |
Return on Equity | |
---|---|
10 Years: | 16% |
5 Years: | 11% |
3 Years: | 7% |
Last Year: | 4% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
Reserves | -3.42 | -3.62 | -4.09 | -2.91 | -2.01 | -1.49 | -0.73 | 0.70 | 1.17 | 1.67 | 2.41 | 2.71 |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.08 | 0.11 | 0.00 | |
0.65 | 1.03 | 1.36 | 1.13 | 0.92 | 1.59 | 1.86 | 2.11 | 1.04 | 1.19 | 1.23 | 1.51 | |
Total Liabilities | 2.23 | 2.41 | 2.27 | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.22 |
1.58 | 1.42 | 0.73 | 0.72 | 2.25 | 1.99 | 1.91 | 1.86 | 2.07 | 2.00 | 1.91 | 1.81 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.80 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
0.64 | 0.98 | 1.53 | 1.69 | 1.65 | 3.17 | 4.21 | 5.94 | 5.13 | 5.93 | 6.83 | 7.40 | |
Total Assets | 2.23 | 2.41 | 2.27 | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.22 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.00 | -0.01 | 0.75 | 0.74 | 0.39 | 1.03 | 0.47 | 2.27 | 0.38 | 0.64 | 0.22 | ||
0.00 | 0.00 | -0.74 | -0.69 | -0.37 | -1.06 | 0.01 | -2.61 | -0.55 | -0.64 | -0.23 | ||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||
Net Cash Flow | 0.00 | -0.01 | 0.01 | 0.05 | 0.01 | -0.03 | 0.48 | -0.34 | -0.17 | 0.00 | 0.00 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 45.29 | 6.67 | 66.36 | 5.59 | 8.62 | 23.17 | 3.22 | 141.51 | 10.14 | 3.58 | 13.04 | 11.97 |
Inventory Days | 267.67 | 335.80 | 136.88 | 121.67 | 52.14 | 2,049.62 | 272.56 | 7.24 | 196.54 | 127.75 | 164.25 | 230.53 |
Days Payable | 121.67 | 150.87 | 76.04 | 76.04 | 5.79 | 1,628.46 | 189.61 | 51.70 | 56.15 | 0.00 | 18.25 | 0.00 |
Cash Conversion Cycle | 191.29 | 191.60 | 127.20 | 51.22 | 54.97 | 444.33 | 86.18 | 97.05 | 150.52 | 131.33 | 159.04 | 242.49 |
Working Capital Days | 29.31 | 38.33 | 22.12 | 85.31 | 175.31 | 498.25 | 30.06 | 79.37 | -60.83 | 143.14 | 162.95 | 41.89 |
ROCE % | -9.60% | -10.81% | -39.30% | 80.00% | 31.50% | 17.66% | 25.48% | 45.14% | 15.67% | 15.02% | 11.35% | 12.61% |
Documents
Announcements
-
Newspaper Add
25 Apr - Published audited financial results for quarter and year ended March 31, 2025, in newspapers.
- Results For The Period Ended March 31, 2025 24 Apr
-
Board Meeting Outcome for Financial Results For The Period Ended March 31, 2025
24 Apr - Audited FY25 financial results approved; net profit Rs.31.61 lakh; unmodified audit opinion.
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
17 Apr - Confirmation of non-applicability of SEBI large corporate funding circular.
-
Board Meeting Intimation for Consideration Of Audited Financial Results For The Period Ended March 31, 2025
16 Apr - Board meeting to approve audited financial results for FY25.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
EBNL is a global healthcare company that manufactures and markets healthcare & nutritional products. It fuses various concepts & principles (both ancient & modern) from Biophysics, Biochemistry, Biotechnology and the Indian system of medicine AYUSH (Ayurveda + Yoga + Unani + Siddha + Homeopathy) to create products. This integration resulted in technology called VedaCeuticals which forms the foundation of all products of EBNL